Protagonist Therapeutics (PTGX) Enterprise Value (2016 - 2026)

Protagonist Therapeutics has reported Enterprise Value for 12 years, with the latest figure at -$547.8 million in Q1 2026.

• Quarterly Enterprise Value rose 4.62% year-over-year to -$547.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$547.8 million (up 4.62% YoY) and the FY2025 annual result came in at -$567.4 million, down 35.44% from the prior year.
• Enterprise Value grew to -$547.8 million in Q1 2026 per PTGX's latest filing, from -$567.4 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$120.5 million in Q2 2022 and troughed at -$576.1 million in Q3 2025.
• A 5-year average of -$396.9 million and a median of -$341.6 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 37.47% in 2022, then plunged 160.15% in 2023.
• Over 5 years, Enterprise Value stood at -$237.3 million in 2022, then slumped by 43.94% to -$341.6 million in 2023, then declined by 22.62% to -$418.9 million in 2024, then tumbled by 35.44% to -$567.4 million in 2025, then increased by 3.45% to -$547.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$547.8 million, -$567.4 million, and -$576.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.